Compare prices and buy Eloralintide from 18 research peptide vendors - also called suppliers or sources. Updated daily.
A 37-amino-acid acylated analog of the pancreatic hormone amylin (CAS 2883634-40-8), developed by Eli Lilly as LY3841136. Unlike cagrilintide, a non-selective amylin and calcitonin receptor agonist, eloralintide preferentially activates the amylin 1 receptor (AMY1R) in vitro. It is in Phase 3 trials for obesity and related conditions and has no FDA approval.
For research purposes only. Not medical advice.
Listed prices for in-stock single vials, before coupon codes. Kits are left out.
Eloralintide (Eli Lilly's LY3841136) is a synthetic analog of amylin, the 37-residue hormone co-secreted with insulin by pancreatic beta cells. The amylin-class background is on the cagrilintide page.
Lilly's discovery paper (Briere and colleagues, Molecular Metabolism, 2025) describes the structure. The main chain carries 37 amino acids, including three non-coded residues at positions 11, 15 and 22. The disulfide bridge of native amylin is replaced with a methylene thioacetal bond between the cysteines at positions 2 and 7, which the authors say enhances chemical stability. A C20 fatty diacid is attached through a linker at the lysine in position 26, so the peptide binds albumin, which extends its half-life. The C-terminus is amidated.
Amylin acts through three amylin receptors (AMY1R, AMY2R and AMY3R), each formed when the calcitonin receptor (CTR) pairs with one of three receptor activity-modifying proteins. In cell lines expressing the human receptors, eloralintide activated AMY1R 12-fold more potently than CTR and 11-fold more potently than AMY3R. The rat receptors showed a different pattern, with AMY1R and AMY3R both activated more potently than CTR. The authors frame that selectivity as the point of the design, contrasting it with cagrilintide, a non-selective agonist, and they also write that the role of the calcitonin receptor in human weight loss remains unclear.
Lilly's first-in-human study (NCT05295940) tested single doses in healthy participants and then 12 weeks of repeated dosing in people with obesity or overweight, reported in Molecular Metabolism (2025) and Diabetes, Obesity and Metabolism (2026).
The Phase 2 trial (NCT06230523), sponsored and funded by Eli Lilly, randomized 263 adults at 46 US sites who had obesity, or overweight with at least one weight-related comorbidity, and no type 2 diabetes. Participants received placebo or one of six eloralintide arms, two of them dose-escalation schemes, for 48 weeks. Billings and colleagues published the results in The Lancet in November 2025, alongside a presentation at ObesityWeek 2025.
Every eloralintide arm met the primary endpoint, percent change in body weight at week 48. The largest mean reduction was 20.1%, versus 0.4% with placebo, under the efficacy estimand, which Lilly defines as the effect had all randomized participants remained on study treatment for 48 weeks. The Lancet abstract rounds the same figure to 20%. Lilly reported that the most common adverse events were mild to moderate gastrointestinal symptoms and fatigue, seen more often in the higher-dose arms.
The Phase 3 program is called ENLIGHTEN, and its first trial started on December 15, 2025. As of October 21, 2026, ClinicalTrials.gov lists five ENLIGHTEN trials, all sponsored by Eli Lilly, recruiting, placebo-controlled and measuring percent change in body weight at week 64 as a primary endpoint.
A second program, AMPLIFY, tests EloraTZP, Lilly's combination of eloralintide with tirzepatide, coded LY900043. Lilly announced Phase 2b results for the combination on September 30, 2026. Its two Phase 3 trials, AMPLIFY-1 (NCT07881432) and AMPLIFY-2 (NCT07881458), were first posted on October 19, 2026 and are not yet recruiting.
Eloralintide has no FDA approval. As of October 21, 2026, Drugs@FDA returns no application for it.
It is also outside the compounding pathway. Section 503A of the FD&C Act lets a pharmacy compound from a bulk substance only if it has a USP or National Formulary monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list. Eloralintide meets none of the three. It has no USP monograph and is a component of no approved drug. It also appears on neither of FDA's bulk-substance nomination lists (503A, updated May 14, 2026, and 503B, updated March 21, 2025). The FDA bulk-substance proceedings (the Category 2 designations, the Pharmacy Compounding Advisory Committee dockets) concern nominated substances, so eloralintide's absence from them reflects no FDA finding about the compound.
Vendors list the compound under its INN, eloralintide, and some shorten it to Elora. The developer code LY3841136 names the same molecule. EloraTZP names a different product, Lilly's eloralintide and tirzepatide combination. Because eloralintide is an amylin analog rather than an incretin, PeptideScouter has mapped no GLP-N generational code to it (see the GLP agonist category for that convention).
PeptideScouter verifies listings against the published CAS number (2883634-40-8) before mapping them, and indexes every mapped listing per milligram so vendors stay comparable.
No. Both are long-acting synthetic analogs of the hormone amylin, but they are different molecules from different developers. Eloralintide is Eli Lilly's compound, coded LY3841136, and cagrilintide is Novo Nordisk's. In Lilly's cell-based studies, eloralintide activated the human amylin 1 receptor (AMY1R) about 12-fold more potently than the calcitonin receptor, while cagrilintide is a non-selective agonist across the amylin and calcitonin receptor family.
No. Eloralintide is investigational and in Phase 3 trials, the ENLIGHTEN program sponsored by Eli Lilly. As of October 21, 2026, Drugs@FDA lists no application for it. It is also not eligible for compounding by a 503A pharmacy, because it has no USP monograph, is not a component of an FDA-approved drug and has not been nominated for FDA's bulk-substance lists. Material sold by research vendors is labelled for laboratory research only, not for human consumption.
In Eli Lilly's 48-week Phase 2 trial of 263 adults with obesity or overweight and without type 2 diabetes, published in The Lancet in November 2025, every eloralintide arm met the primary endpoint. The largest mean body-weight reduction was 20.1%, versus 0.4% with placebo, under the efficacy estimand, which estimates the effect had all randomized participants stayed on treatment. Lilly reported gastrointestinal symptoms and fatigue as the most common adverse events, more frequent at higher doses.
EloraTZP is Eli Lilly's investigational combination of eloralintide with tirzepatide, coded LY900043. Lilly announced Phase 2b results on September 30, 2026, and its two Phase 3 trials, AMPLIFY-1 and AMPLIFY-2, were first posted on ClinicalTrials.gov on October 19, 2026. It is a separate product from eloralintide alone, and PeptideScouter indexes eloralintide on this page as a single compound.
Eloralintide is sold by 18 research peptide vendors indexed on PeptideScouter. The lowest listed in-stock prices are at By Oneday ($8.25/mg), Renova Peptides ($8.90/mg) and Glow Aminos ($9.95/mg). The table above compares all 18 tracked listings by vendor, refreshed daily.
16 of the 18 indexed vendors currently have Eloralintide in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
By Oneday currently lists Eloralintide at $8.25/mg, the lowest listed price across 18 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $4.95/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 18 vendors listing Eloralintide publish a PeptideScouter code, worth 10% to 20% off. Applied, the lowest effective price falls from $5.50/mg listed to $4.95/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
10 mg vials list from $82.49 (median $119.99 across 14 in-stock listings) and 5 mg vials list from $64.99 (median $75.00 across 2 in-stock listings). Per milligram, listed prices run from $5.50/mg to $18.00/mg across 18 listings. Prices are refreshed daily.
Eloralintide's CAS Registry Number is 2883634-40-8. It is also sold as Elora, LY3841136, Eloralintide (Amylin Receptor Agonist).